Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00135967
Status:
COMPLETED
Last Update Posted:
2005-12-06
First Post:
2005-08-25
Brief Title:
Mycophenolate Mofetil in Membranous Nephropathy
Sponsor:
Radboud University Medical Center
Organization:
Radboud University Medical Center
Study Overview
Official Title:
Treatment of Patients With Membranous Nephropathy and Renal Insufficiency With Mycophenolate Mofetil and Prednisone a Pilot Study
Status:
COMPLETED
Status Verified Date:
2005-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients with idiopathic membranous nephropathy and renal insufficiency are at risk for end-stage renal disease ESRD Treatment with cyclophosphamide is currently used as a treatment modality Mycophenolate mofetil is a new immunosuppressive agent with fewer side effects
In this pilot study patients with membranous nephropathy and renal failure will be treated with mycophenolate mofetil and prednisone The outcome will be compared with historical controls treated with a similar regimen containing cyclophosphamide
In this pilot study patients with membranous nephropathy and renal failure will be treated with mycophenolate mofetil and prednisone The outcome will be compared with historical controls treated with a similar regimen containing cyclophosphamide
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None